title: Availability of cefixime 400 mg tablets--United States, April 2008.
abstract: The only current CDC-recommended options for treating Neisseria gonorrhoeae infections are from a single class of antibiotics, the cephalosporins. Within this class, ceftriaxone, available only as an injection, is the recommended treatment for all types of gonorrhea infections (i.e., urogenital, rectal, and pharyngeal). The only oral agent recommended currently by CDC for treatment of uncomplicated urogenital or rectal gonorrhea is a single dose of cefixime 400 mg. Availability of cefixime had been limited since July 2002, when Wyeth Pharmaceuticals (Collegeville, Pennsylvania) discontinued manufacturing cefixime tablets in the United States. Beginning in April 2008, cefixime (Suprax) 400 mg tablets are again available in the United States.
mesh_terms: D000900:Anti-Bacterial Agents / Q000600:supply & distribution*; D020682:Cefixime / Q000600:supply & distribution*; D006069:Gonorrhea / Q000188:drug therapy; D006801:Humans; D014481:United States
chemical_list: D000900:Anti-Bacterial Agents; D020682:Cefixime